Pelargonium sidoides and acute bronchitis:
A randomized, double-blind, placebo-controlled, multi-center study evaluated 217 adults aged 18 to 66 years with acute bronchitis. Participants in the active arm (n=108) received Pelargonium sidoides, 30 drops (1.5 mL) or placebo 3 times daily, for 7 days. Changes in bronchitis severity score (BSS: cough, sputum, rales/rhonchi, chest pain at cough, dyspnoea) were assessed. At the end of treatment, the BSS decreased by 7.6 points in the active treatment group and by 5.3 points in the placebo group. Only minor side-effects were reported. (3)
Pelargonium sidoides (EPs 7630) was reported to benefit both adults and children with acute bronchitis. A total of 2099 patients aged 0-93 years were included in this study. Participants received EPs 7630 for 14 days at a dose determined by a participant’s age. During treatment, the average Bronchitis Severity Score (BSS: cough, sputum, rales/rhonchi, chest pain at cough, dyspnoea) of all patients decreased from 7.1 points at baseline to 1.0 points at last visit. For children, average BSS decreased from 6.3 points to 0.9 points. For children aged 3 years or less, average mean BSS decreased from 5.2 points to 1.2 points. No serious side-effects were reported. (2)
